COVID booster shots will become available in September

COVID-19 booster shots from Pfizer-BioNTech and Moderna will be available starting the week of September 20, the White House announced.

The booster shots will be administered by the Department of Health and Human Services, pending FDA approval. The shots are intended to be administered eight months after an individual receives a second dose of the vaccine.

“The COVID-19 vaccines that are authorized in the United States have been remarkably effective, even against the widespread Delta variant,” Surgeon General Vivek Murphy said in a statement. “But we know that even highly effective vaccines become less effective over time.”

When the booster shots become available, many frontline workers, including healthcare professionals, teachers and seniors, will be eligible. However, the plan is still waiting on FDA approval.

“I want to be very clear: This plan is pending the FDA conducting an independent evaluation of the safety and effectiveness of a third dose of the Pfizer and Moderna mRNA vaccines and the CDC’s Advisory Committee on Immunization Practices issuing booster dose recommendations based on a thorough review of the evidence,” Murphy said.

The new plan comes as COVID-19 cases continue to rise. More than 621,000 Americans have lost their lives due to the virus, according to the CDC. In addition, more than 37 million cases were reported in the last 30 days. More than 72% of U.S. adults are fully vaccinated.

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.